For BRCA carriers with advanced HER2-negative BC, phase III clinical trials have demonstrated improved tolerability and superior efficacy of PARPi monotherapy in comparison to standard chemotherapy [11,12]. This evidence concerns the gene ERBB2 and breast cancer.